Zilretta Promising in Phase 2 Trial
Zilretta (triamcinolone acetonide extended release) is an intra-articular injection for managing osteoarthritis (OA) knee pain. A Phase 2 study of the treatment examined blood glucose levels in patients with type 2 diabetes and OA knee pain.1
Also by this Author
During the double blind, randomized study, data showed that patient’s blood glucose levels were significantly lower after administration of Zilretta compared with those in patients treated with an injection of immediate release triamcinolone acetonide in crystalline suspension (TAcs). Blood glucose levels were measured 72 hours prior to injection through 72 hours after the injection. Adverse event rates were low and similar between treatment groups. Adverse events were all Grade 1 or 2, and no Zilretta-treated patients experienced an index-knee or injection-related adverse event.
Zilretta is not intended for repeat administration. The treatment was approved by the U.S. Food and Drug Administration as the first extended release intra-articular injection for OA. Its formulation combines triamcinolone acetonide with a poly lactic-co-glycolic acid (PLGA) matrix that provides pain relief for more than 12 weeks.